Compare UK & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UK | PPCB |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | China | Australia |
| Employees | 42 | 2 |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.3M |
| IPO Year | N/A | N/A |
| Metric | UK | PPCB |
|---|---|---|
| Price | $2.98 | $0.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 341.0K | ★ 5.8M |
| Earning Date | 03-24-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.09 |
| 52 Week High | $5.90 | $10.69 |
| Indicator | UK | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 71.40 | 34.44 |
| Support Level | $0.75 | N/A |
| Resistance Level | N/A | $0.13 |
| Average True Range (ATR) | 0.57 | 0.01 |
| MACD | 0.27 | 0.00 |
| Stochastic Oscillator | 50.36 | 8.10 |
Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. Company provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has three operating segments: Workspace membership, and Other services. The Workspace membership segment generates the majority of the company's revenue.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.